CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1%

CRISPR Therapeutics AG (NASDAQ:CRSP) shares rose 1% during mid-day trading on Friday . The company traded as high as $54.94 and last traded at $54.27. Approximately 375,067 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 1,789,485 shares. The stock had previously closed at $53.73.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wolfe Research assumed coverage on CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Barclays raised their price objective on CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. Citigroup raised their price objective on CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Chardan Capital raised their price objective on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, Morgan Stanley raised their price objective on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research report on Monday, February 26th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $76.29.

CRISPR Therapeutics Stock Performance

The company has a 50-day simple moving average of $70.57 and a 200-day simple moving average of $63.95. The stock has a market cap of $4.58 billion, a P/E ratio of -27.50 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. During the same quarter in the previous year, the firm posted ($1.41) EPS. The company’s revenue for the quarter was up 3253.3% compared to the same quarter last year. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the transaction, the chief executive officer now owns 187,377 shares in the company, valued at approximately $15,057,615.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now directly owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the sale, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at $15,057,615.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,992 shares of company stock worth $9,157,835. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. CWM LLC increased its stake in shares of CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after buying an additional 260 shares during the period. Tradewinds Capital Management LLC grew its stake in shares of CRISPR Therapeutics by 545.5% during the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after purchasing an additional 600 shares during the period. Blue Trust Inc. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $32,000. Headlands Technologies LLC acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth $34,000. Finally, Bourgeon Capital Management LLC grew its stake in shares of CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.